Government-Owned Inventions; Availability for Licensing, 14257-14259 [2014-05472]
Download as PDF
<![CDATA[
14257
Federal Register / Vol. 79, No. 49 / Thursday, March 13, 2014 / Notices
(NINDS), and the Office of AIDS
Research (OAR). While these programs
differ, their underlying concept is the
same; they require U.S. scientists to
collaborate with scientists from other
countries in order to conduct
scientifically meritorious investigations
of mutual interest to both countries. The
award, when possible. This information
is needed to evaluate the effectiveness
of these programs across NIH.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
128.
proposed evaluation requests
information about (1) accomplishments
of the awards, (2) unique findings or
opportunities due to the international
collaborations, and (3) successes and
challenges of these collaborations. The
information will be collected one year
into the award and at the end of the
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Type of respondents
Principal Investigators Administrative Supplements ........................................
Principal Investigators Other Mechanisms ......................................................
Dated: March 7, 2014.
Vivian Horovitch-Kelley,
NCI Project Clearance Liaison, National
Institutes of Health.
[FR Doc. 2014–05514 Filed 3–12–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
SUMMARY:
TKELLEY on DSK3SPTVN1PROD with NOTICES
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by writing to the
indicated licensing contact at the Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
VerDate Mar<15>2010
17:33 Mar 12, 2014
Jkt 232001
24
52
Rabies Vaccine for the Oral
Immunization of Domesticated
Animals, Wildlife and Feral Animals
Description of Technology: This
invention, developed by the CDC and
collaborators, entails a live, attenuated
recombinant rabies virus vaccine that
can elicit an effective anti-rabies
immune response in animal recipients.
Inoculation with a live, attenuated,
rabies virus allows for the optimized
production of immunity in the absence
of pathogenicity. Oral administration of
rabies vaccines is often a preferred route
of vaccine delivery because it is most
effective in wildlife. Unfortunately,
availability of an oral vaccine for
canines has been a significant hurdle to
date.
This vaccine technology could be
used for immunization of stray dogs by
an oral route. In developing nations,
more than 90% of human exposure
events and 99% of human deaths due to
rabies are caused by rabid dogs. Using
this vaccine with a broadly
implemented oral vaccination strategy
provides a promising opportunity for
reducing transmission of rabies between
stray dogs and, thereby, increasing
protection for people.
Potential Commercial Applications:
• Wildlife and humane shelter rabies
prevention and control programs
• Improved rabies vaccines for pets and
livestock
• Humane, targeted approach to
elimination of rabies reservoirs in
feral animal populations
Competitive Advantages:
• Safe and effective
• Oral immunization is the most
practical and efficient method of
rabies vaccination of wildlife and
feral animals
• Vaccine has demonstrated protection
in vivo
• Recombinant, non-neuroinvasive
virus expressing a neuroinvasive
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
1
2
Average
burden per
response
(in hours)
Total
annual
burden
hours
1
1
24
104
glycoprotein and/or pro-apoptotis
gene safely induces a robust and
desirable immunological response
Development Stage:
• In vitro data available
• In vivo data available (animal)
Inventors: Charles E. Rupprecht
(CDC), et al.
Intellectual Property: HHS Reference
No. E–470–2013/0—U.S. Patent No.
7,074,413 issued 11 Jul 2006.
Licensing Contact: Whitney Blair, J.D.,
M.P.H.; 301–435–4937; whitney.blair@
nih.gov.
Cable-Line Safety System: Electro/
Hydraulic Emergency Stop Device for a
Winch, Drum or Capstan
Description of Technology: This CDCdeveloped invention entails a system of
electrical and hydraulic circuits used to
stop a rotating winch in an emergency.
Amongst other locations, one stop
switch can be positioned on a capstan
winch horn. This location makes it
available to a victim entangled in rope
being retrieved on a gypsy drum. As
designed, the stop circuit could be used
with an electrically, hydraulically or
pneumatically operated winch. A
variant of this safety system has been
successfully tested on a purse seining
fishing vessel in Alaskan waters.
Potential Commercial Applications:
• Retrofitting existing winches for
additional safety and adherence to
possible future regulations
• Specifically designed and tested for
the marine/fishing industries
• Applications in mining, construction,
forestry, and/or off-road automotive
industries
• Workers’ well-being concern groups
• Insurers of fishing vessels; also
mining, construction and forestry
operations
• Manufacturers of cable reel trailers
and wire-drawing machinery
Competitive Advantages:
E:\FR\FM\13MRN1.SGM
13MRN1
14258
Federal Register / Vol. 79, No. 49 / Thursday, March 13, 2014 / Notices
• Complies with numerous
international safety regulations
requiring winches, drums and
capstans to have a master on/off
switch in easy reach for worker safety
• Can be packaged as a ‘retrofit kit’ for
integration with current commercial
winch/drum usage
Development Stage:
• In situ data available (on-site)
• Prototype
Inventors: Chelsea Woodward, Todd
Ruff, Curtis Clark, Robert McKibbin,
John Bevan, Greg Miller, Wayne Howie,
Louis Martin, Jennifer Lincoln (all
inventors from CDC–NIOSH).
Intellectual Property: HHS Reference
No. E–355–2013/0—Research Tool.
Patent protection is not being pursued
for this technology.
Related Technologies:
• HHS Reference No. E–504–2013/0
• HHS Reference No. E–567–2013/0
• HHS Reference No. E–568–2013/0
• HHS Reference No. E–643–2013/0
Licensing Contact: Whitney Blair, J.D.,
M.P.H.; 301–435–4937; whitney.blair@
nih.gov.
TKELLEY on DSK3SPTVN1PROD with NOTICES
Lead Detection Wipes for Potentially
Contaminated Surfaces
Description of Technology: This CDCdeveloped invention relates to a method
for the detection of lead on surfaces
(such as, for example, skin, floors, walls,
windows sills) using a ‘handwipe’
system and a chemical test effecting a
characteristic color change if
contaminating lead is present. This
invention is especially useful in
detecting the presence of lead on skin
and assessing the effectiveness of hand
washing in removal of lead from the
skin of exposed individuals. Further,
this invention is useful in field
evaluation for the presence of lead,
exposure of individuals to lead, and the
effectiveness of its subsequent removal
in the workplace, home, school, and
similar environments.
Potential Commercial Applications:
• Suitable for lead-testing surfaces such
as floors, walls, windowsills and
human skin
• Evaluation of lead-removal
effectiveness from surfaces in homes,
hospitals, workplaces and schools
• Confirming hand/skin/shoe/clothingwashing effectiveness of lead removal
for military, target range personnel
Competitive Advantages:
• Simple color-change readout indicates
the presence of lead on a surface
• Rapid test; lead concentration can be
inferred by degree of color shift
• Safe for use on skin
Development Stage:
VerDate Mar<15>2010
17:33 Mar 12, 2014
Jkt 232001
• In vitro data available
• In situ data available (on-site)
Inventors: Eric J. Esswein, Mark F.
Boeniger, Kevin E. Ashley (all of CDC).
Publications:
1. Ashley K. Field-portable methods for
monitoring occupational exposures to
metals. J Chem Health Saf.
2010;17(3):22–8. [https://dx.doi.org/
10.1016/j.jchas.2009.07.002]
2. NIOSH Manual of Analytical Methods
(NMAM), Fourth Edition. Method 9105,
Issue 1—Lead in Dust Wipes by
Chemical Spot Test Method
(Colorimetric Screening Method), 15
March 2003. U.S. National Institute for
Occupational Safety and Health
(NIOSH), Cincinnati, OH. [https://
www.cdc.gov/niosh/docs/2003–154/
pdfs/9105.pdf ]
3. Esswein EJ, et al. Handwipe Method for
Removing Lead from Skin. Journal of ASTM
International. 2011 May;8(5):Paper ID
JAI103527. [https://dx.doi.org/10.1520/
JAI103527]
Intellectual Property: HHS Reference
No. E–336–2013/0—U.S. Patent No.
6,248,593 issued 19 Jun 2001.
Related Technology:
• HHS Reference No. E–356–2013/0
• HHS Reference No. E–359–2013/0
Licensing Contact: Whitney Blair, J.D.,
M.P.H.; 301–435–4937; whitney.blair@
nih.gov.
Mining Safety: Personal Dust Monitor
Filters for Accurate, Quantifiable
Spectrometric Analysis and Assessment
of Worker Exposure Levels
Description of Technology: This CDCdeveloped invention pertains to a novel
dust monitor filter that is specially
constructed of organic materials for
spectrometric analysis, ultimately
allowing for detection and accurate
quantification of a particular chosen
analyte (e.g., crystalline silica/quartz
dust that may lead to silicosis).
For miners, the risk of lung disease
increases with the extent of dust
exposure, and coal worker’s
pneumoconiosis (aka, black lung
disease) and silicosis are still dangers
routinely faced by those in the industry.
Expectedly, both the concentration and
the composition of airborne particulate
matter present in mining environments
are points of regulatory concern. For
some time, collecting airborne dust
samples and subsequent determination
of quartz content have been integral for
assessing mine worker exposure and
demonstrating compliance with US
Federal regulations.
Unfortunately, highly accurate
spectrometric detection and
quantification of particulate exposure
has not always been possible. Generally,
the filters used in existing oscillating
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
microbalances (such as the TEOM®
monitor) have been specially designed
to for hydrophobicity, in order to retain
as little moisture as possible on the
filter. These specialized hydrophobic
filters (and/or their mounting
components) contain inorganic
compounds that cannot be readily
subjected to thermal or chemical
destruction—a necessary first step of
many instrumental analytical methods,
such as spectroscopy.
This CDC-developed filter consists of
entirely ashable material, making it
ideal for spectrometric analysis and
rapid exposure assessment. As an
example, this dust monitor filter can be
made entirely of organic materials and
designed for quick, easy ashing that will
not produce interference with the
spectroscopic characteristics of the
chosen analyte(s). Further, filter ashing
can be carried out by a variety of
methods: thermal ashing, microwave
ashing, low temperature ashing, or
chemical destruction.
Potential Commercial Applications:
• Personal dust monitors worn
wherever dust exposure levels and the
presence of potentially injurious
materials is evaluated
• Occupationally-mandated
pneumoconiosis, asbestosis and/or
silicosis prevention and monitoring
programs, for complying with safety
regulations
• Miners’ wellness concern groups and
insurance companies
Competitive Advantages:
• Novel dust-monitoring instrument
capable of providing near rapid
particulate exposure information to
miners/users
• Improves upon older technology by
allowing for accurate detection and
quantification of chosen analyte(s)
and, unlike other filters, does not
produce overlap or interfere with
spectroscopic analysis
• Filter can be easily ashed for analysis
by thermal ashing, microwave ashing,
low temperature ashing, or chemical
destruction
Development Stage:
• Early-stage
• In vitro data available
Publication:
Tuchman DP. Implementing infrared
determination of quartz particulates on
novel filters for a prototype dust
monitor. J Environ Monit. 2008
May;10(5):671–8. [PMID 18449405]
Intellectual Property: HHS Reference
No. E–312–2013/0—U.S. Patent No.
7,947,503 issued 24 May 2011.
Licensing Contact: Whitney Blair, J.D.,
M.P.H.; 301–435–4937; whitney.blair@
nih.gov.
E:\FR\FM\13MRN1.SGM
13MRN1
Federal Register / Vol. 79, No. 49 / Thursday, March 13, 2014 / Notices
TKELLEY on DSK3SPTVN1PROD with NOTICES
Computer Controlled Aerosol
Generator With Multi-Walled Carbon
Nanotube Inhalation Testing
Capabilities
Description of Technology: This
invention pertains to a CDC–NIOSH
developed sonic aerosol generator that
provides a controllable, stable
concentration of particulate aerosol over
a long period of time for aerosol
exposure studies. Specifically, in situ
testing data indicate uniform aerosol
stability can be maintainable for greater
than 30 hours at concentrations of 15
mg/m3 or more. Additionally, the
technology was specifically developed
for, and validated in, animal studies
assessing exposure to airborne multiwalled carbon nanotubes (MWCNT). It
has been suggested that workers may be
at risk for exposure to nanosized
particles during the manufacture,
handling, and cleanup of engineered
nanomaterials. Compared to other
technologies, this NIOSH aerosol
generator is particularly helpful when
used for generating high testing
concentrations of MWCNT aerosols that
more accurately represent particulate
levels that may be seen in a workplace
environment.
Potential Commercial Applications:
• Studying the size and shape of the
aerosolized particles produced from
simple vibrations of bulk material
• Toxicological investigations and risk
assessment of aerosol exposures,
especially those related to
nanoparticle manufacturing.
• Any aerosolization application where
the aggregating ‘‘bird’s nest’’
tendencies of airborne multi-walled
carbon nanotubes must be overcome
Competitive Advantages:
• Fully automated system with
integrated feedback control for
optimized stability in testing
• Maintains concentration of aerosols
for >30 hours at concentrations of 15
mg/cubic meter or more
• Capable of generating high
concentrations of aerosols that more
accurately represent the levels seen in
a workplace environment
• System insures that each run
produces a constant particle
concentration, air flow, pressure,
temperature and humidity within a
testing chamber
Development Stage:
• In vitro data available
• In vivo data available (animal)
• In situ data available (on-site)
• Prototype
Inventors: Walter G. McKinney, David
G. Frazer, Bean Chen (all of CDC)
Publications:
VerDate Mar<15>2010
17:33 Mar 12, 2014
Jkt 232001
1. McKinney W, et al. Computer controlled
multi-walled carbon nanotube inhalation
exposure system. Inhal Toxicol. 2009
Oct;21(12):1053–61. [PMID 19555230]
2. Porter DW, et al. Acute pulmonary doseresponses to inhaled multi-walled
carbon nanotubes. Nanotoxicology. 2013
Nov;7:1179–94. [PMID 22881873]
3. Porter DW, et al. Mouse pulmonary doseand time course-responses induced by
exposure to multi-walled carbon
nanotubes. Toxicology. 2010 Mar
10;269(2–3):136–47. [PMID 19857541]
4. Chen BT, et al. Multi-walled carbon
nanotubes: sampling criteria and aerosol
characterization. Inhal Toxicol. 2012
Oct;24(12):798–820. [PMID 23033994]
Intellectual Property: HHS Reference
No. E–156–2013/0—U.S. Patent
Application No. 12/871,453 filed 30
Aug 2010.
Licensing Contact: Whitney Blair, J.D.,
M.P.H.; 301–435–4937; whitney.blair@
nih.gov.
Dated: March 10, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2014–05472 Filed 3–12–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel; Collaborative
Perinatal Project (CPP) Mortality Linkage
Study Data Coordinating Center.
Date: April 8, 2014.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To provide concept review of
proposed concept review.
Place: National Institutes of Health, 6100
Executive Boulevard, Rockville, MD 20852,
(Telephone Conference Call).
Contact Person: Sathasiva B. Kandasamy,
Ph.D., Scientific Review Officer, Division of
Scientific Review, National Institute of Child
Health and Human Development, 6100
Executive Boulevard, Rockville, MD 20892–
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
14259
9304, (301) 435–6680, skandasa@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS).
Dated: March 7, 2014.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–05474 Filed 3–12–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Resource-Related Research Projects in Lung
Diseases.
Date: April 8, 2014.
Time: 8:30 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites Chevy Chase
Pavilion, 4300 Military Road NW.,
Washington, MD 20015.
Contact Person: Susan Wohler Sunnarborg,
Ph.D. Scientific Review Officer, Office of
Scientific Review/DERA, National, Heart,
Lung, and Blood Institute, 6701 Rockledge
Drive, Room 7182, Bethesda, MD 20892
sunnarborgsw@nhlbi.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Ancillary Studies in Clinical Trials.
Date: April 11, 2014.
Time: 8:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Garden Inn Washington DC/
Bethesda, 7301 Waverly St., Bethesda, MD
20814.
Contact Person: Kristen Page, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
E:\FR\FM\13MRN1.SGM
13MRN1
]]>Agencies
[Federal Register Volume 79, Number 49 (Thursday, March 13, 2014)]
[Notices]
[Pages 14257-14259]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-05472]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to
receive copies of the patent applications.
Rabies Vaccine for the Oral Immunization of Domesticated Animals,
Wildlife and Feral Animals
Description of Technology: This invention, developed by the CDC and
collaborators, entails a live, attenuated recombinant rabies virus
vaccine that can elicit an effective anti-rabies immune response in
animal recipients. Inoculation with a live, attenuated, rabies virus
allows for the optimized production of immunity in the absence of
pathogenicity. Oral administration of rabies vaccines is often a
preferred route of vaccine delivery because it is most effective in
wildlife. Unfortunately, availability of an oral vaccine for canines
has been a significant hurdle to date.
This vaccine technology could be used for immunization of stray
dogs by an oral route. In developing nations, more than 90% of human
exposure events and 99% of human deaths due to rabies are caused by
rabid dogs. Using this vaccine with a broadly implemented oral
vaccination strategy provides a promising opportunity for reducing
transmission of rabies between stray dogs and, thereby, increasing
protection for people.
Potential Commercial Applications:
Wildlife and humane shelter rabies prevention and control
programs
Improved rabies vaccines for pets and livestock
Humane, targeted approach to elimination of rabies reservoirs
in feral animal populations
Competitive Advantages:
Safe and effective
Oral immunization is the most practical and efficient method
of rabies vaccination of wildlife and feral animals
Vaccine has demonstrated protection in vivo
Recombinant, non-neuroinvasive virus expressing a
neuroinvasive glycoprotein and/or pro-apoptotis gene safely induces a
robust and desirable immunological response
Development Stage:
In vitro data available
In vivo data available (animal)
Inventors: Charles E. Rupprecht (CDC), et al.
Intellectual Property: HHS Reference No. E-470-2013/0--U.S. Patent
No. 7,074,413 issued 11 Jul 2006.
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
whitney.blair@nih.gov.
Cable-Line Safety System: Electro/Hydraulic Emergency Stop Device for a
Winch, Drum or Capstan
Description of Technology: This CDC-developed invention entails a
system of electrical and hydraulic circuits used to stop a rotating
winch in an emergency. Amongst other locations, one stop switch can be
positioned on a capstan winch horn. This location makes it available to
a victim entangled in rope being retrieved on a gypsy drum. As
designed, the stop circuit could be used with an electrically,
hydraulically or pneumatically operated winch. A variant of this safety
system has been successfully tested on a purse seining fishing vessel
in Alaskan waters.
Potential Commercial Applications:
Retrofitting existing winches for additional safety and
adherence to possible future regulations
Specifically designed and tested for the marine/fishing
industries
Applications in mining, construction, forestry, and/or off-
road automotive industries
Workers' well-being concern groups
Insurers of fishing vessels; also mining, construction and
forestry operations
Manufacturers of cable reel trailers and wire-drawing
machinery
Competitive Advantages:
[[Page 14258]]
Complies with numerous international safety regulations
requiring winches, drums and capstans to have a master on/off switch in
easy reach for worker safety
Can be packaged as a `retrofit kit' for integration with
current commercial winch/drum usage
Development Stage:
In situ data available (on-site)
Prototype
Inventors: Chelsea Woodward, Todd Ruff, Curtis Clark, Robert
McKibbin, John Bevan, Greg Miller, Wayne Howie, Louis Martin, Jennifer
Lincoln (all inventors from CDC-NIOSH).
Intellectual Property: HHS Reference No. E-355-2013/0--Research
Tool. Patent protection is not being pursued for this technology.
Related Technologies:
HHS Reference No. E-504-2013/0
HHS Reference No. E-567-2013/0
HHS Reference No. E-568-2013/0
HHS Reference No. E-643-2013/0
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
whitney.blair@nih.gov.
Lead Detection Wipes for Potentially Contaminated Surfaces
Description of Technology: This CDC-developed invention relates to
a method for the detection of lead on surfaces (such as, for example,
skin, floors, walls, windows sills) using a `handwipe' system and a
chemical test effecting a characteristic color change if contaminating
lead is present. This invention is especially useful in detecting the
presence of lead on skin and assessing the effectiveness of hand
washing in removal of lead from the skin of exposed individuals.
Further, this invention is useful in field evaluation for the presence
of lead, exposure of individuals to lead, and the effectiveness of its
subsequent removal in the workplace, home, school, and similar
environments.
Potential Commercial Applications:
Suitable for lead-testing surfaces such as floors, walls,
windowsills and human skin
Evaluation of lead-removal effectiveness from surfaces in
homes, hospitals, workplaces and schools
Confirming hand/skin/shoe/clothing-washing effectiveness of
lead removal for military, target range personnel
Competitive Advantages:
Simple color-change readout indicates the presence of lead on
a surface
Rapid test; lead concentration can be inferred by degree of
color shift
Safe for use on skin
Development Stage:
In vitro data available
In situ data available (on-site)
Inventors: Eric J. Esswein, Mark F. Boeniger, Kevin E. Ashley (all
of CDC).
Publications:
1. Ashley K. Field-portable methods for monitoring occupational
exposures to metals. J Chem Health Saf. 2010;17(3):22-8. [https://dx.doi.org/10.1016/j.jchas.2009.07.002]
2. NIOSH Manual of Analytical Methods (NMAM), Fourth Edition. Method
9105, Issue 1--Lead in Dust Wipes by Chemical Spot Test Method
(Colorimetric Screening Method), 15 March 2003. U.S. National
Institute for Occupational Safety and Health (NIOSH), Cincinnati,
OH. [https://www.cdc.gov/niosh/docs/2003-154/pdfs/9105.pdf ]
3. Esswein EJ, et al. Handwipe Method for Removing Lead from
Skin. Journal of ASTM International. 2011 May;8(5):Paper ID
JAI103527. [https://dx.doi.org/10.1520/JAI103527]
Intellectual Property: HHS Reference No. E-336-2013/0--U.S. Patent
No. 6,248,593 issued 19 Jun 2001.
Related Technology:
HHS Reference No. E-356-2013/0
HHS Reference No. E-359-2013/0
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
whitney.blair@nih.gov.
Mining Safety: Personal Dust Monitor Filters for Accurate, Quantifiable
Spectrometric Analysis and Assessment of Worker Exposure Levels
Description of Technology: This CDC-developed invention pertains to
a novel dust monitor filter that is specially constructed of organic
materials for spectrometric analysis, ultimately allowing for detection
and accurate quantification of a particular chosen analyte (e.g.,
crystalline silica/quartz dust that may lead to silicosis).
For miners, the risk of lung disease increases with the extent of
dust exposure, and coal worker's pneumoconiosis (aka, black lung
disease) and silicosis are still dangers routinely faced by those in
the industry. Expectedly, both the concentration and the composition of
airborne particulate matter present in mining environments are points
of regulatory concern. For some time, collecting airborne dust samples
and subsequent determination of quartz content have been integral for
assessing mine worker exposure and demonstrating compliance with US
Federal regulations.
Unfortunately, highly accurate spectrometric detection and
quantification of particulate exposure has not always been possible.
Generally, the filters used in existing oscillating microbalances (such
as the TEOM[supreg] monitor) have been specially designed to for
hydrophobicity, in order to retain as little moisture as possible on
the filter. These specialized hydrophobic filters (and/or their
mounting components) contain inorganic compounds that cannot be readily
subjected to thermal or chemical destruction--a necessary first step of
many instrumental analytical methods, such as spectroscopy.
This CDC-developed filter consists of entirely ashable material,
making it ideal for spectrometric analysis and rapid exposure
assessment. As an example, this dust monitor filter can be made
entirely of organic materials and designed for quick, easy ashing that
will not produce interference with the spectroscopic characteristics of
the chosen analyte(s). Further, filter ashing can be carried out by a
variety of methods: thermal ashing, microwave ashing, low temperature
ashing, or chemical destruction.
Potential Commercial Applications:
Personal dust monitors worn wherever dust exposure levels and
the presence of potentially injurious materials is evaluated
Occupationally-mandated pneumoconiosis, asbestosis and/or
silicosis prevention and monitoring programs, for complying with safety
regulations
Miners' wellness concern groups and insurance companies
Competitive Advantages:
Novel dust-monitoring instrument capable of providing near
rapid particulate exposure information to miners/users
Improves upon older technology by allowing for accurate
detection and quantification of chosen analyte(s) and, unlike other
filters, does not produce overlap or interfere with spectroscopic
analysis
Filter can be easily ashed for analysis by thermal ashing,
microwave ashing, low temperature ashing, or chemical destruction
Development Stage:
Early-stage
In vitro data available
Publication:
Tuchman DP. Implementing infrared determination of quartz
particulates on novel filters for a prototype dust monitor. J
Environ Monit. 2008 May;10(5):671-8. [PMID 18449405]
Intellectual Property: HHS Reference No. E-312-2013/0--U.S. Patent
No. 7,947,503 issued 24 May 2011.
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
whitney.blair@nih.gov.
[[Page 14259]]
Computer Controlled Aerosol Generator With Multi-Walled Carbon Nanotube
Inhalation Testing Capabilities
Description of Technology: This invention pertains to a CDC-NIOSH
developed sonic aerosol generator that provides a controllable, stable
concentration of particulate aerosol over a long period of time for
aerosol exposure studies. Specifically, in situ testing data indicate
uniform aerosol stability can be maintainable for greater than 30 hours
at concentrations of 15 mg/m3 or more. Additionally, the technology was
specifically developed for, and validated in, animal studies assessing
exposure to airborne multi-walled carbon nanotubes (MWCNT). It has been
suggested that workers may be at risk for exposure to nanosized
particles during the manufacture, handling, and cleanup of engineered
nanomaterials. Compared to other technologies, this NIOSH aerosol
generator is particularly helpful when used for generating high testing
concentrations of MWCNT aerosols that more accurately represent
particulate levels that may be seen in a workplace environment.
Potential Commercial Applications:
Studying the size and shape of the aerosolized particles
produced from simple vibrations of bulk material
Toxicological investigations and risk assessment of aerosol
exposures, especially those related to nanoparticle manufacturing.
Any aerosolization application where the aggregating ``bird's
nest'' tendencies of airborne multi-walled carbon nanotubes must be
overcome
Competitive Advantages:
Fully automated system with integrated feedback control for
optimized stability in testing
Maintains concentration of aerosols for >30 hours at
concentrations of 15 mg/cubic meter or more
Capable of generating high concentrations of aerosols that
more accurately represent the levels seen in a workplace environment
System insures that each run produces a constant particle
concentration, air flow, pressure, temperature and humidity within a
testing chamber
Development Stage:
In vitro data available
In vivo data available (animal)
In situ data available (on-site)
Prototype
Inventors: Walter G. McKinney, David G. Frazer, Bean Chen (all of
CDC)
Publications:
1. McKinney W, et al. Computer controlled multi-walled carbon
nanotube inhalation exposure system. Inhal Toxicol. 2009
Oct;21(12):1053-61. [PMID 19555230]
2. Porter DW, et al. Acute pulmonary dose-responses to inhaled
multi-walled carbon nanotubes. Nanotoxicology. 2013 Nov;7:1179-94.
[PMID 22881873]
3. Porter DW, et al. Mouse pulmonary dose- and time course-responses
induced by exposure to multi-walled carbon nanotubes. Toxicology.
2010 Mar 10;269(2-3):136-47. [PMID 19857541]
4. Chen BT, et al. Multi-walled carbon nanotubes: sampling criteria
and aerosol characterization. Inhal Toxicol. 2012 Oct;24(12):798-
820. [PMID 23033994]
Intellectual Property: HHS Reference No. E-156-2013/0--U.S. Patent
Application No. 12/871,453 filed 30 Aug 2010.
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
whitney.blair@nih.gov.
Dated: March 10, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2014-05472 Filed 3-12-14; 8:45 am]
BILLING CODE 4140-01-P
